|
NCI Launches New Integrative Cancer Biology Program
Every day, researchers make new discoveries about cancer that elucidate the
disease process, but also demonstrate its increasing complexity. To address
this complexity, the National Cancer Institute (NCI) has announced $14.9
million in funding for the Integrative Cancer Biology Program (ICBP). "We need
to hone our efforts toward an integrated approach to the study of cancer," said
NCI Director Dr. Andrew C. von Eschenbach. "ICBP will take advantage of the
explosion in research and technology to comprehensively weave together the
disparate pieces of knowledge and reveal how cancer develops and progresses
within the context of the human system."
ICBP will work toward this goal by combining efforts from the entire spectrum of cancer researchers, from wet-lab biologists and computer
scientists to epidemiologists and
clinicians, through nine integrative
biology centers: Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts Institute of Technology, Ohio State University, University Hospital of Cleveland, Duke University, Vanderbilt University Medical Center, Stanford University, and Lawrence Berkeley National Laboratory.
Read
more
Clinical Trial System of Future
The recent voluntary recall of rofecoxib (Vioxx) by Merck & Co., Inc.,
illustrates all too well the importance of well-designed clinical trials and
vigilant surveillance for any new drug or medical product. Some 3 years after
FDA approval and widespread use, rofecoxib was found to be associated with a
two-fold increased risk of cardiovascular toxicities in people who took the
drug for 18 months or longer in a clinical trial to prevent colon adenomas.
The recall has resulted in the careful review of any cardiovascular effects of
other drugs in the class of drugs known as COX-2 inhibitors. COX-2 inhibitors
have shown tremendous promise in the prevention and treatment of several
different cancers. NCI is sponsoring more than 40 clinical trials with the
COX-2 inhibitor celecoxib (Celebrex), most of which are phase I and include
studies on cancer prevention and treatment. Based on the safety concerns
reported in the rofecoxib trials and the possibility that these concerns may
extend to other COX-2 inhibitors, such as celecoxib, NCI is rapidly reviewing
data from our studies of COX-2 inhibitors with our Data Safety Monitoring
Boards (DSMBs), starting with the largest studies with the longest follow-up.
And, as appropriate, we have added additional cardiovascular expertise to our
prevention and treatment trial DSMBs.
Clinical trials are our most powerful weapons in the war against cancer. And the rofecoxib recall is further affirmation that our patients must be clearly informed about the safety and side effects of any new or experimental treatments or drugs they are taking. It also highlights the need for evolution of our national clinical trials program.
Read
more
|
The NCI Cancer Bulletin is produced by the National Cancer Institute
(NCI). NCI, which was established in 1937, leads the national effort to
eliminate the suffering and death due to cancer. Through basic, clinical, and
population-based biomedical research and training, NCI conducts and supports
research that will lead to a future in which we can identify the environmental
and genetic causes of cancer, prevent cancer before it starts, identify cancers
that do develop at the earliest stage, eliminate cancers through innovative
treatment interventions, and biologically control those cancers that we cannot
eliminate so they become manageable, chronic diseases.
For more information on cancer, call 1-800-4-CANCER or visit
http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at
ncicancerbulletin@mail.nih.gov.
|
|